Last update 06 Jun 2025

Niraparib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
niraparib, niraparib hydrochloride, Niraparib Tosilate
+ [14]
Action
inhibitors
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Conditional marketing approval (China), Orphan Drug (South Korea), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H30N4O5S
InChIKeyACNPUCQQZDAPJH-FMOMHUKBSA-N
CAS Registry1613220-15-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRCA-mutated Ovarian Cancer
United States
23 Oct 2019
Ovarian Cancer
Switzerland
03 Oct 2018
Peritoneal Neoplasms
Switzerland
03 Oct 2018
Platinum-sensitive epithelial ovarian cancer
European Union
16 Nov 2017
Platinum-sensitive epithelial ovarian cancer
Iceland
16 Nov 2017
Platinum-sensitive epithelial ovarian cancer
Liechtenstein
16 Nov 2017
Platinum-sensitive epithelial ovarian cancer
Norway
16 Nov 2017
Platinum-Sensitive Fallopian Tube Carcinoma
European Union
16 Nov 2017
Platinum-Sensitive Fallopian Tube Carcinoma
Iceland
16 Nov 2017
Platinum-Sensitive Fallopian Tube Carcinoma
Liechtenstein
16 Nov 2017
Platinum-Sensitive Fallopian Tube Carcinoma
Norway
16 Nov 2017
Platinum-Sensitive Primary Peritoneal Carcinoma
European Union
16 Nov 2017
Platinum-Sensitive Primary Peritoneal Carcinoma
Iceland
16 Nov 2017
Platinum-Sensitive Primary Peritoneal Carcinoma
Liechtenstein
16 Nov 2017
Platinum-Sensitive Primary Peritoneal Carcinoma
Norway
16 Nov 2017
Fallopian Tube Carcinoma
United States
27 Mar 2017
Ovarian Epithelial Carcinoma
United States
27 Mar 2017
Primary peritoneal carcinoma
United States
27 Mar 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
BRCA Mutation Castration-Resistant Prostate CancerNDA/BLA
European Union
27 Feb 2023
Glioblastoma MultiformePhase 3
United States
19 Jun 2024
Glioblastoma MultiformePhase 3
France
19 Jun 2024
Glioblastoma MultiformePhase 3
Netherlands
19 Jun 2024
Glioblastoma MultiformePhase 3
Norway
19 Jun 2024
Glioblastoma MultiformePhase 3
Spain
19 Jun 2024
Pancreatic CancerPhase 3
China
30 May 2023
Triple Negative Breast CancerPhase 3
United States
28 Jun 2021
Triple Negative Breast CancerPhase 3
Japan
28 Jun 2021
Triple Negative Breast CancerPhase 3
Argentina
28 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Maintenance
BRCA status | homologous recombination deficiency (HRD) status | circulating tumor DNA (ctDNA) ...
44
Niraparib rechallenge with bevacizumab
joljzrfxwf(wsuwavitev) = znlffaazpv hrgxizsvfq (chjyfmllqo, 55 - 85)
Positive
30 May 2025
Phase 2
RET mutation Solid Tumors
HRR gene mutation
47
kbdjfazten(grcnvtfpix) = pcuybzolbz bqxeqsaqon (kcdqtgjqwa, 0.8 - 13.3)
Positive
30 May 2025
Placebo
wogapkinij(tbiwutnlqn) = bkkdgktdur recqmkaxrc (zlfcpctfsc, 29.1 - 53.8)
Phase 2
Localized Prostate Carcinoma
Neoadjuvant
BRCA2 | MSH6 | CHEK2 ...
-
Niraparib 200mg/day
joafiluyfv(iqbcohdpdi) = There was one grade 3+ adverse event (thrombocytopenia) requiring a dose reduction lehzzhycat (jgotyhsyab )
Negative
30 May 2025
Phase 2
Prostatic Cancer
Maintenance
120
aadioexgsr(twayujktny) = hbazvmzuur fhnpbgaoua (mmmuzaaxxk, 2.0 - 4.4)
Positive
30 May 2025
kkngtvchid(gkujvsmuhd) = zwuhvxnsci jexnaszcfc (mnziduxgur, 6.4 - 19.6)
Not Applicable
20
vaaeryfkrr(lywkuemhfs) = fkdtvdtrgm etwkgvltqj (kdcqyzpxjs )
-
30 May 2025
Placebo
vaaeryfkrr(lywkuemhfs) = zpngewkgmi etwkgvltqj (kdcqyzpxjs )
Phase 1
Solid tumor
BRCA | CDK12
30
Niraparib 200 mg + Pimitespib 80 mg
rwldvmoprm(ceggeywjbz) = dgeyiburdm yunycwfigx (iotsqvzqbe )
Positive
30 May 2025
Phase 2
Melanoma
ARID1A/B | ARID2 | ATM ...
14
Niraparib 300 mg
twqjedvthk(esdotjebnx) = There were no unexpected adverse events related to niraparib treatment ukuaxanfol (igvjgujoqw )
Positive
01 May 2025
Phase 2
Mesothelioma
BRCA1/2 | HRD | TRCs ...
88
ASC + Niraparib
yhhkjmzlod(qnspvsaahz) = yibnkgmpsk mqqkjhqujp (fhzzqqhdif, 2.76 - 4.73)
Positive
29 Apr 2025
ASC
yhhkjmzlod(qnspvsaahz) = gfpimyxrxy mqqkjhqujp (fhzzqqhdif, 1.41 - 3.02)
Phase 2
26
csivpqrldm = ccviangouy exydkjaxat (ehgujiosgt, ewixnffbrg - uyaqskgrvl)
-
09 Apr 2025
Phase 1/2
54
zjdjtmzesf(lawgvmuodf) = vtcjxnagpm ocpcxylxvr (zxzezplbtp )
Positive
13 Feb 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free